CME Credit: EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know

Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient’s tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are emerging now, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. Thoracic surgeons are key members of the multidisciplinary care team, playing an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies.

This PeerView Live MasterClass & Case Forum educational symposium will focus on the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings and provide practical guidance for optimally integrating targeted therapies in practice or clinical trials. Multidisciplinary discussions on the latest practice-changing data will highlight important implications of utilizing EGFR-targeted therapy as part of multimodal treatment for surgeons and the broader lung cancer care team.

This CME activity is provided by PVI, PeerView Institute for Medical Education.

This activity is supported by an independent educational grant from AstraZeneca.

 Register for the event at PeerView.com/2023EGFR-Live.